ライフサイエンスコーパス: hepatitis B virus

1 the correct schedule and before exposure to hepatitis B virus.

2 A3s against retroviruses, parvoviruses, and hepatitis B virus.

3 gle-stranded DNA (ssDNA) parvovirus, but not hepatitis B virus.

4 The study of hepatitis B virus and development of curative antivirals

5 es in the longer term through the control of hepatitis B virus and hepatitis C virus infections by va

6 ecrosis factors [screening tests looking for hepatitis B virus and hepatitis C virus status and laten

7 ruses (Africa for HIV and southeast Asia for hepatitis B virus and hepatitis C virus).

8 We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral

9 Sharing the same envelope proteins, hepatitis B virus and hepatitis delta virus use the sodi

10 eptor mediating hepatocyte-specific entry of hepatitis B virus and hepatitis delta virus.

11 We also confirm suppression of hepatitis B virus and poliovirus by ARB.

12 on-Pfizer monkey virus), two hepadnaviruses (hepatitis B virus and woodchuck hepatitis virus), and an

13 sponsible for significant disease in humans (hepatitis B virus) and have been reported from a diverse

14 pentavalent (diphtheria, tetanus, pertussis, hepatitis B virus, and Haemophilus influenzae type b), y

15 d DARE for studies of the prevalence of HIV, hepatitis B virus, and hepatitis C virus in people with

16 hepatitis C virus with and without alcohol, hepatitis B virus, and hepatocellular carcinoma (group I

17 tomegalovirus, human immunodeficiency virus, hepatitis B virus, and neonatal herpes simplex virus, fr

18 Bx, restores replication of an HBx-deficient hepatitis B virus, and rescues wild-type hepatitis B vir

19 s SERS assay was applied to the detection of Hepatitis B virus antigen (HBsAg) in human blood plasma.

20 The low detection limit for Hepatitis B virus antigen was estimated to be 0.01IU/mL.

21 s pollen allergens and the PreS protein from hepatitis B virus as a carrier were expressed in Escheri

22 ses, including influenza A virus (FLUAV) and hepatitis B virus but not retroviruses.

23 e show that cell-culture and patient-derived hepatitis B virus can establish persistent infection for

24 The hepatitis B virus capsid (core) can be composed of eithe

25 Chronic hepatitis B virus carriers are at risk of developing fib

26 Hepatitis B virus causes chronic infections in 250 milli

27 rcumcision, home birth, tribal scarring, and hepatitis B virus coinfection.

28 model of hepatitis B: infectious transgenic hepatitis B virus composed of a complete virus plus a fo

29 pid, high yield and economical production of Hepatitis B Virus core (HBc) particles.

30 s associated with a similar modest change in hepatitis B virus core antigen polypeptide (HBcAg/p21) s

31 ) and VP2 (aa141-155) epitopes of EV71 using hepatitis B virus core protein (HBc) as a carrier, desig

32 Hepatitis B virus core protein has 183 amino acids divid

33 Hepatitis B virus core protein has multiple roles in the

34 for novel biomarkers toward better defining hepatitis B virus cure should occur in parallel with dev

35 will likely be needed to achieve functional hepatitis B virus cure.

36 The hepatitis B virus deploys the hepatitis B virus X protei

37 The Pol of duck hepatitis B virus (DHBV) also localized to the mitochond

38 (FISH)-based assay for the detection of duck hepatitis B virus (DHBV) cccDNA and HBV nuclear DNA in e

39 For the avian hepadnavirus duck hepatitis B virus (DHBV), CTD is dephosphorylated subseq

40 antly differ according to the VR definition (hepatitis B virus DNA <200, < 2000, < 20,000 IU/mL) or d

41 The peak levels of hepatitis B virus DNA and hepatitis B core-related antig

42 Rebound of hepatitis B virus DNA and hepatitis B core-related antig

43 toring of CHB patients with detectable serum hepatitis B virus DNA in European tertiary referral cent

44 =1 alanine aminotransferase and 37% had >/=1 hepatitis B virus DNA level assessed annually.

45 Hepatitis B virus DNA targets in human serum are simulta

46 nts had alanine aminotransferase and 44% had hepatitis B virus DNA testing; hepatitis B e antigen and

47 Hepatitis B virus encodes the regulatory HBx protein who

48 f viruses, including HIV, hepatitis C virus, hepatitis B virus, enterovirus 71, influenza virus, resp

49 Myrcludex B, a peptide inhibitor of hepatitis B virus entry, is assumed to specifically targ

50 New inhibitors of hepatitis B virus entry, replication, assembly, or secre

51 sue of Immunity, Ou and colleagues show that hepatitis B virus exploits these naturally occurring imm

52 The management for occupational HIV or hepatitis B virus exposures includes postexposure prophy

53 relieves the inhibition to allow productive hepatitis B virus gene expression.

54 ates with extrachromosomal reporters and the hepatitis B virus genome, suggesting a direct mechanism

55 Chronic infection by hepatitis B virus (HBV) afflicts hundreds of millions wo

56 valence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID.

57 Hepatitis B virus (HBV) and hepatitis C virus (HCV) are

58 Hepatitis B virus (HBV) and hepatitis C virus (HCV) caus

59 Advances in therapy for hepatitis B virus (HBV) and hepatitis C virus (HCV) have

60 Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infe

61 uss common challenges to the burden posed by hepatitis B virus (HBV) and hepatitis C virus (HCV), to

62 Infections with the human hepatitis B virus (HBV) and hepatitis D virus (HDV) depe

63 tions and displays excellent potency against hepatitis B virus (HBV) and varicella-zoster virus (VZV)

64 We investigated hepatitis B virus (HBV) antibodies and galactomannan enz

65 Outcomes of chronic infection with hepatitis B virus (HBV) are varied, with increased morbi

66 Assembly of hepatitis B virus (HBV) begins with packaging of the pre

67 In contrast to horizontal transmission of hepatitis B virus (HBV) between adults, which often lead

68 transferase 1 (PRMT1) only modestly increase hepatitis B virus (HBV) biosynthesis.

69 Cell culture (cc)-derived hepatitis B virus (HBV) can infect differentiated HepaRG

70 been used to track the assembly of the T = 4 hepatitis B virus (HBV) capsid in real time.

71 Hepatitis B virus (HBV) capsid proteins (Cps) assemble a

72 ices to analyze in real time the assembly of Hepatitis B Virus (HBV) capsids below the pseudocritical

73 The hepatitis B virus (HBV) causes acute and chronic liver i

74 Hepatitis B virus (HBV) chronic infection affects up to

75 Hepatitis B virus (HBV) chronically infects 250 million

76 re (ACLF) were developed in patients with no Hepatitis B virus (HBV) cirrhosis (CANONIC study).

77 rus (HIV)-infected patients with and without hepatitis B virus (HBV) coinfection on antiretroviral th

78 HDV requires a hepatitis B virus (HBV) coinfection to provide HDV with

79 se associated with persistent infection with hepatitis B virus (HBV) continues to be a major health p

80 Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serolog

81 tion state of the C-terminal domain (CTD) of hepatitis B virus (HBV) core or capsid protein is highly

82 Mutations in the hepatitis B virus (HBV) core promoter (CP) have been sho

83 Multiple subunits of the hepatitis B virus (HBV) core protein (HBc) assemble into

84 Though the hepatitis B virus (HBV) core protein is an important par

85 The hepatitis B virus (HBV) core protein is essential for HB

86 Hepatitis B virus (HBV) covalently closed circular (CCC)

87 tion and the factors involved.IMPORTANCE The hepatitis B virus (HBV) covalently closed circular (CCC)

88 Currently in vitro infection with hepatitis B virus (HBV) depends on cell culture-derived

89 Serum levels of hepatitis B virus (HBV) DNA (</=2000 IU/mL) and hepatiti

90 ified APOBEC deaminases as enzymes targeting hepatitis B virus (HBV) DNA in the nucleus thus affectin

91 ith nucleos(t)ide analogues (NAs) suppresses hepatitis B virus (HBV) DNA production but does not affe

92 r chronic hepatitis B involve suppression of hepatitis B virus (HBV) DNA with the use of nucleoside a

93 nd 95%, 99%, 100%, and 100% had undetectable hepatitis B virus (HBV) DNA, respectively.

94 plantation, 39 (72%) patients had detectable hepatitis B virus (HBV) DNA, with a median of 4.5 log co

95 Anti-hepatitis B virus (HBV) drugs are currently limited to n

96 The management of hepatitis B virus (HBV) e antigen-positive viremic patie

97 Hepatitis B virus (HBV) encodes a multifunction reverse

98 the human immunodeficiency virus (HIV) gene, hepatitis B virus (HBV) gene and human T-lymphotropic vi

99 To evaluate how hepatitis B virus (HBV) genetic variation affected progr

100 Hepatitis B virus (HBV) genotype and its role in disease

101 Hepatitis B virus (HBV) genotype C causes prolonged chro

102 Hepatitis B virus (HBV) genotypes can influence treatmen

103 Hepatitis B virus (HBV) has a detrimental effect on huma

104 The hepatitis B virus (HBV) has been described as stealth vi

105 Reactivation of hepatitis B virus (HBV) has been reported in hepatitis C

106 tion, and HBV-driven tumor growth.IMPORTANCE Hepatitis B virus (HBV) HBx protein plays a critical rol

107 Hepatitis B virus (HBV) immunization has been effectivel

108 dvice 1: Clinicians should vaccinate against hepatitis B virus (HBV) in all unvaccinated adults (incl

109 The basis for the persistence of hepatitis B virus (HBV) in hepatocytes, even in the pres

110 Despite the introduction of immunisation for hepatitis B virus (HBV) in the 1990s, HBV-related morbid

111 Chronic hepatitis B virus (HBV) infection affects 240 million pe

112 Hepatitis B virus (HBV) infection afflicts millions worl

113 iviral treatment-naive patients with chronic hepatitis B virus (HBV) infection but not in treatment-e

114 optosis proteins (cIAPs) impair clearance of hepatitis B virus (HBV) infection by preventing TNF-medi

115 Hepatitis B virus (HBV) infection can result in a spectr

116 (RNAi)-based therapeutic ARC-520 for chronic hepatitis B virus (HBV) infection consists of a melittin

117 tive prevention and treatment interventions, hepatitis B virus (HBV) infection continues to cause nea

118 What are the screening guidelines for hepatitis B virus (HBV) infection for asymptomatic, nonp

119 rugs in patients with HBeAg-negative chronic hepatitis B virus (HBV) infection in a non-inferiority s

120 rugs in patients with HBeAg-positive chronic hepatitis B virus (HBV) infection in a non-inferiority s

121 iral compounds.The lack of models that mimic hepatitis B virus (HBV) infection in a physiologically r

122 However, studies of hepatitis B virus (HBV) infection in chimpanzees have in

123 iated with diabetes in patients with chronic hepatitis B virus (HBV) infection in North America are u

124 Despite the high burden of hepatitis B virus (HBV) infection in sub-Saharan Africa,

125 The number of persons with chronic hepatitis B virus (HBV) infection in the United States i

126 regarding the prevalence and distribution of hepatitis B virus (HBV) infection in U.S. Hispanics/Lati

127 Chronic hepatitis B virus (HBV) infection is a common cause of t

128 Chronic hepatitis B virus (HBV) infection is a global public hea

129 Chronic hepatitis B virus (HBV) infection is a global public hea

130 Chronic hepatitis B virus (HBV) infection is a major factor in h

131 Chronic hepatitis B virus (HBV) infection is a major global heal

132 Chronic hepatitis B virus (HBV) infection is a major risk factor

133 Chronic hepatitis B virus (HBV) infection is a major risk factor

134 Hepatitis B virus (HBV) infection is a serious public he

135 Persistent hepatitis B virus (HBV) infection is established by the

136 Chronic hepatitis B virus (HBV) infection is estimated to affect

137 Chronic Hepatitis B Virus (HBV) infection is generally not curab

138 Hepatitis B virus (HBV) infection is more common in Afri

139 Chronic hepatitis B virus (HBV) infection is partly responsible

140 Chronic hepatitis B virus (HBV) infection is prevalent, deadly,

141 A hallmark of chronic hepatitis B virus (HBV) infection is the functional impa

142 Chronic hepatitis B virus (HBV) infection often develop into cir

143 on or cirrhosis due to other causes, such as hepatitis B virus (HBV) infection or alcohol, remains un

144 he heterogeneous clinical courses of chronic hepatitis B virus (HBV) infection reflect the complex ho

145 Chronic hepatitis B virus (HBV) infection remains the most commo

146 Hepatitis B virus (HBV) infection represents a significa

147 Vaccine failure with chronic hepatitis B virus (HBV) infection still develops in chil

148 Patients with resolved hepatitis B virus (HBV) infection who are treated for he

149 It can occur with active or resolved hepatitis B virus (HBV) infection with a clinical spectr

150 ions have among the highest rates of chronic hepatitis B virus (HBV) infection worldwide, but little

151 hepatitis C virus (HCV) infection, 17.9% had hepatitis B virus (HBV) infection, and 2.2% had both.

152 achieving better treatment and prevention of hepatitis B virus (HBV) infection, anti-HBV agents targe

153 govern distinct clinical phases of a chronic hepatitis B virus (HBV) infection-immune tolerant (IT),

154 s and are particularly promising for chronic hepatitis B virus (HBV) infection.

155 n patients with current or prior exposure to hepatitis B virus (HBV) infection.

156 the liver diseases that result from chronic hepatitis B virus (HBV) infection.

157 atory effect are rarely addressed in chronic hepatitis B virus (HBV) infection.

158 surface Ag (HBsAg) seroconversion in chronic hepatitis B virus (HBV) infection.

159 Greenland remains a highly endemic area for hepatitis B virus (HBV) infection.

160 th metabolic risk factors, for patients with hepatitis B virus (HBV) infection.

161 rcinoma (HCC), often associated with chronic hepatitis B virus (HBV) infection.

162 age to care can reduce the burden of chronic hepatitis B virus (HBV) infection.

163 An estimated 20 000 new hepatitis B virus (HBV) infections occur each year in th

164 patitis B surface antigen (HBsAg) in chronic hepatitis B virus (HBV) infections of China remains uncl

165 presents an endpoint of treatment of chronic hepatitis B virus (HBV) infections.

166 BACKGROUND & AIMS: Hepatitis B virus (HBV) infects hepatocytes, but the mec

167 Hepatitis B virus (HBV) infects hundreds of millions of

168 Hepatitis B virus (HBV) is a major global health concern

169 Hepatitis B virus (HBV) is a major human pathogen, and a

170 plication-competent viral capsids.IMPORTANCE Hepatitis B virus (HBV) is a major human pathogen, and n

171 Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) is a major route of HBV transmis

172 Chronic infection with hepatitis B virus (HBV) is a risk factor for developing

173 Chronic infection with hepatitis B virus (HBV) is a risk factor for developing

174 Hepatitis B virus (HBV) is an important global human pat

175 hronic hepatitis B (CHB), failure to control hepatitis B virus (HBV) is associated with T cell dysfun

176 Hepatitis B virus (HBV) is endemic in sub-Saharan Africa

177 antiviral regimens with no activity against hepatitis B virus (HBV) may increase the risk for HBV re

178 Hepatitis B virus (HBV) modulates microRNA (miRNA) expre

179 We examined the associations between hepatitis B virus (HBV) or hepatitis C virus (HCV) infec

180 ), most cases of which are related to either hepatitis B virus (HBV) or hepatitis C virus (HCV).

181 -replicative (HBV DNA <20,000 IU/mL) chronic hepatitis B virus (HBV) patients.

182 ron gamma and interleukin 10) to overlapping hepatitis B virus (HBV) peptides (preS, S, preC, core, a

183 Chronic infection with hepatitis B virus (HBV) progresses through different pha

184 racterizes and defines the clinical value of hepatitis B virus (HBV) quasispecies with reverse transc

185 Reports were published recently on hepatitis B virus (HBV) reactivation (HBV-R) in patients

186 Hepatitis B virus (HBV) reactivation during immunosuppre

187 Hepatitis B virus (HBV) reactivation has been reported i

188 Hepatitis B virus (HBV) reactivation in hepatitis B surf

189 udies report conflicting data on the risk of hepatitis B virus (HBV) reactivation in rheumatologic pa

190 tumor chemotherapy regimens pose a risk for hepatitis B virus (HBV) reactivation, but screening and

191 Immunosuppressants can induce hepatitis B virus (HBV) reactivation; however, informati

192 ate cotransporting polypeptide (NTCP) as the hepatitis B virus (HBV) receptor enabled researchers to

193 noglobulin (HBIg) is effective in preventing hepatitis B virus (HBV) recurrence after liver transplan

194 an integral component of prophylaxis against hepatitis B virus (HBV) recurrence in liver transplantat

195 al or mother-to-child transmission (MTCT) of hepatitis B virus (HBV) remains the major risk factor fo

196 eraction mechanisms for achieving an optimal hepatitis B virus (HBV) replication have been largely un

197 Hepatitis B Virus (HBV) replication in hepatocytes is re

198 es, such as entecavir or tenofovir, suppress hepatitis B virus (HBV) replication, improve liver funct

199 To understand subcellular sites of hepatitis B virus (HBV) replication, we visualized core

200 osphates (dNTPs) are essential for efficient hepatitis B virus (HBV) replication.

201 Persistent or chronic infection with the hepatitis B virus (HBV) represents one of the most commo

202 Infection with hepatitis B virus (HBV) results in disparate degrees of

203 ation, there is still evidence of suboptimal hepatitis B virus (HBV) screening among patients at high

204 pies according to hepatitis C virus (HCV) or hepatitis B virus (HBV) status.

205 B vaccine, despite loss of antibody against hepatitis B virus (HBV) surface antigen (anti-HBs), is u

206 natural killer (NK) cells in the process of hepatitis B virus (HBV) surface antigen (HBsAg) clearanc

207 Humans vaccinated with hepatitis B virus (HBV) surface antigen (HBsAg) sometime

208 REP 2139 clears circulating hepatitis B virus (HBV) surface antigen (HBsAg), enhanci

209 Here, we investigated the CTD in empty hepatitis B virus (HBV) T=4 capsids.

210 New hepatitis B virus (HBV) therapies are expected to have b

211 Despite immunoprophylaxis, hepatitis B virus (HBV) transmission in highly viremic m

212 ctiveness of strategies to prevent perinatal hepatitis B virus (HBV) transmission in the United State

213 fumarate (TDF) in reducing mother-to-infant hepatitis B virus (HBV) transmissions is not clearly und

214 Hepatitis B virus (HBV) transmitted from infected mother

215 Here, the CTD from the human hepatitis B virus (HBV) was found to be dephosphorylated

216 Sequences from hepatitis B virus (HBV) were detected in 7 individuals w

217 tide sequence characteristic of DNA from the hepatitis B virus (HBV) with a detection limit of 85 pM.

218 Hepatitis B virus (HBV), a small enveloped DNA virus, ch

219 to identify NAFLD, hepatitis C virus (HCV), hepatitis B virus (HBV), alcoholic liver disease (ALD),

220 Previous estimates of the burden of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) amo

221 cquiring human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV).

222 f 47,591 adults wait-listed for LT from HCV, hepatitis B virus (HBV), and nonalcoholic steatohepatiti

223 pidemiology of HIV, hepatitis C virus (HCV), hepatitis B virus (HBV), and tuberculosis in prisoners.

224 Hepatitis B virus (HBV), belonging to Hepadnaviridae fam

225 role of the transcriptional template of the hepatitis B virus (HBV), covalently closed circular DNA

226 atitis delta virus (HDV), a satellite of the hepatitis B virus (HBV), increases viral liver disease s

227 is in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), NAFLD, and alcoholic liver dise

228 th infections by either hepatitis A virus or hepatitis B virus (HBV), or a noninfectious cause for th

229 otype 1 hepatitis C virus (HCV) and 203 with hepatitis B virus (HBV), respectively.

230 of the reverse transcriptase protein (RT) of hepatitis B virus (HBV), sampled from patients with rapi

231 Here, using mutational analyses of hepatitis B virus (HBV), we found that Hsp90 stimulates

232 eral common loci associated with the risk of hepatitis B virus (HBV)- or hepatitis C virus (HCV)-rela

233 The incidences of chronic hepatitis B (CHB), Hepatitis B virus (HBV)-associated cirrhosis and HBV-ass

234 Hepatitis B virus (HBV)-encoded X protein (HBx) plays a

235 pha elicits a pleiotropic antiviral state in hepatitis B virus (HBV)-infected hepatocytes, but whethe

236 We have sampled healthy and hepatitis B virus (HBV)-infected human livers to probe f

237 disturbance of Mg(2+) homeostasis on chronic hepatitis B virus (HBV)-infected natural killer (NK) and

238 Elucidating mechanisms of hepatitis B virus (HBV)-mediated hepatocarcinogenesis is

239 In this study hepatitis B virus (HBV)-naive older adults received thre

240 n conducted on the genetic susceptibility of hepatitis B virus (HBV)-related hepatocellular carcinoma

241 Activation of hepatitis B virus (HBV)-specific CD8 T cells by therapeu

242 Activated and hepatitis B virus (HBV)-specific T cells, particularly t

243 cy virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV).

244 is delta virus (HDV) is a satellite virus of hepatitis B virus (HBV).

245 on, Kupffer cells (KCs) likely interact with hepatitis B virus (HBV).

246 f death for patients coinfected with HIV and hepatitis B virus (HBV).

247 compatible with acute, resolved, and chronic hepatitis B virus (HBV)infection but might also signify

248 elevated in HCV+ liver biopsies compared to hepatitis B virus (HBV+) and uninfected samples.

249 d with hepatitis C virus [HCV] and five with hepatitis B virus [HBV]) of 600 HIV-infected patients wh

250 tors and centered on CTNNB1 (alcohol), TP53 (hepatitis B virus, HBV) and AXIN1.

251 Hepatitis B viruses (HBVs), which are enveloped viruses

252 Hepadnaviruses (hepatitis B viruses [HBVs]) are the only animal viruses

253 Treatment of hepatitis B virus, hepatitis C virus, and acute T cell-m

254 a number of major human pathogens, including hepatitis B virus, hepatitis C virus, and malaria.

255 re found in the sera from patients with AIH, hepatitis B virus, hepatitis C virus, and nonalcoholic s

256 The prevalence of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis a

257 ent hepatitis B virus, and rescues wild-type hepatitis B virus in a DDB1-knockdown background.

258 of the pregenomic RNA encapsidation in human Hepatitis B virus in vivo using a coarse-grained molecul

259 FNalpha was confirmed in HEV gt1, but not in Hepatitis B Virus infected animals.

260 drug-induced liver injury DILI (22%), acute hepatitis B virus infection (12%), autoimmune hepatitis

261 C virus infection (41%), alcohol (39%), and hepatitis B virus infection (22%) the commonest etiologi

262 an guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucleos(t)ide

263 A cross-sectional analysis of prevalence of hepatitis B virus infection (HBV) among rural couples wa

264 Chronic hepatitis B virus infection is a leading cause of cirrho

265 f LT, center, and hepatitis C virus (HCV) or hepatitis B virus infection) with non-HIV-infected contr

266 B vaccine is an effective measure to prevent hepatitis B virus infection.

267 with HIV infection are at increased risk for hepatitis B virus infection.

268 and obesity; 12.5% (95% CI: 10.6-14.3%) for hepatitis B virus infection; 29.1% (95% CI: 23.6-34.5%)

269 copies per mL); HLA-B*5701-negative; had no hepatitis B virus infection; screening genotypes showing

270 However, hepatitis B virus inhibited the AIM2 inflammasome by red

271 For the discovery of hepatitis B virus integration sites from probe capture d

272 Hepatitis B virus is one of the smallest human pathogens

273 HCV is an RNA virus that, unlike hepatitis B virus, is unable to integrate into the host

274 might perform distinct functions during the hepatitis B virus lifecycle.

275 9 HDV-infected patients, 25 individuals with hepatitis B virus monoinfection and 18 healthy controls.

276 Formation of the hepatitis B virus nucleocapsid is an essential step in t

277 Chronic hepatitis B virus or hepatitis C co-infection was allowe

278 Patients with co-infection (hepatitis B virus or HIV infection), evidence of decompe

279 Other viruses, such as hepatitis B virus or human herpesvirus 8 (HHV-8), establ

280 e (PR = 2.57; 95% CI: 2.33-2.84; P = 0.001), hepatitis B virus (PR = 1.32; 95% CI: 1.09-1.59; P = 0.0

281 lly regulates several direct target genes of hepatitis B virus protein X (HBx), a viral co-factor.

282 Hepatitis B virus reactivation (HBVr) is an important co

283 Hepatitis B virus reactivation is a newly identified saf

284 Hepatitis B virus reactivation, defined as an abrupt inc

285 transfer of T cells engineered to express a hepatitis B virus-specific (HBV-specific) T cell recepto

286 were available on covariates, such as HIV or hepatitis B virus status, for subgroup analyses.

287 axis, mother-to-child transmission (MTCT) of Hepatitis B Virus still occurs in approximately 2-5% of

288 yme as signal amplifier for determination of hepatitis B virus surface antigen (HBsAg).

289 for malignant disease, testing positive for hepatitis B virus surface antigen, pregnancy, creatinine

290 genomes, such as those of papillomavirus or hepatitis B virus that induce specific cancers.

291 In hepatitis B virus, this is manifested as a virion where

292 th on extrachromosomal reporter genes and on hepatitis B virus transcription.

293 ment of hepatitis C virus and suppression of hepatitis B virus, treatment and management principles f

294 onses to protein-based vaccines, such as the Hepatitis B virus vaccine formulated in alum.

295 n of CpG-C, using an interval similar to the Hepatitis B virus vaccine.

296 in Egypt (1054 [84%] of 1251 patients), and hepatitis B virus was the leading cause in the other Afr

297 of this algorithm is demonstrated using the Hepatitis B virus X (HBx) protein, a protein of unknown

298 The hepatitis B virus deploys the hepatitis B virus X protein (HBx) as a suppressor of hos

299 mined in HCC that spontaneously developed in hepatitis B virus X protein (HBx) transgenic mice.

300 The enigmatic hepatitis B virus X protein was used as a test case for